Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Pharming Group ( (PHAR) ) just unveiled an announcement.
Pharming Group reported significant financial growth in the third quarter of 2025, with a 30% increase in total revenues to $97.3 million compared to the previous year. RUCONEST® and Joenja® saw substantial revenue increases, driven by patient growth and new market entries. The company also announced strategic decisions, including withdrawing RUCONEST® from non-U.S. markets to focus on more profitable opportunities and a leadership change with Leverne Marsh set to become Chief Commercial Officer in January 2026. These developments, alongside a raised revenue guidance for 2025, underscore Pharming’s strategic focus on enhancing its market position and addressing unmet medical needs.
The most recent analyst rating on (PHAR) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Pharming Group stock, see the PHAR Stock Forecast page.
Spark’s Take on PHAR Stock
According to Spark, TipRanks’ AI Analyst, PHAR is a Neutral.
Pharming Group’s overall stock score is driven by strong technical analysis and positive earnings call sentiment, indicating potential growth. However, financial performance challenges, particularly in profitability and valuation, weigh down the score. The company’s stable balance sheet and cash flow improvements provide a foundation for future growth if profitability can be enhanced.
To see Spark’s full report on PHAR stock, click here.
More about Pharming Group
Pharming Group N.V. is a biotechnology company based in the Netherlands, focusing on the development and commercialization of innovative protein replacement therapies and precision medicines. Its primary products include RUCONEST®, used for treating acute hereditary angioedema (HAE) attacks, and Joenja® (leniolisib), targeting activated phosphoinositide 3-kinase delta syndrome (APDS). The company is actively expanding its market presence in the U.S. and Europe, with a strong emphasis on rare diseases.
Average Trading Volume: 12,109
Technical Sentiment Signal: Buy
Current Market Cap: $899.6M
For a thorough assessment of PHAR stock, go to TipRanks’ Stock Analysis page.